You searched for "macular oedema"
Diabetic Macular Oedema
1 December 2013
| Pouya Alaghband
Diabetes mellitus is a metabolic disorder that affects the metabolism of all three categories of carbohydrates, lipids and proteins. This condition is characterised by chronic hyperglycaemia [1]. This can cause end organ damage. The estimated worldwide diabetes prevalence for 2010...
Treatment of diabetic macular oedema
1 June 2014
| Samantha S Mann
|
Retina / Uvea / Vitreous
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
Insights in resistant diabetic macular oedema
5 August 2022
| Sofia Rokerya
|
Retina / Uvea / Vitreous
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Management of diabetic macular oedema (DMO)
1 February 2018
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
Intravitreal triamcinolone for uveitic macular oedema
1 June 2016
| Saruban Pasu
|
Retina / Uvea / Vitreous
|
Intravitreal injection, macular edema, steroid, triamcinolone, uveitis
This paper from South Korea reports on a prospective, double blind, randomised clinical study designed to evaluate the additional benefit of intravitreal triamcinolone (TA) administration for noninfectious uveitic macular oedema as an adjunct therapy to systemic anti-inflammatory treatment. Patients were...
Intravitreal aflibercept for diabetic macular oedema
1 December 2015
| Brian Ang
|
Ophthalmology
The VISTA and VIVID randomised phase 3 trial were designed to compare the efficacy and safety of intravitreal aflibercept injections versus laser photocoagulation for diabetic macular oedema (DMO). A total of 872 patients with centrally involving DMO were recruited, and...
Epiretinal membranes in uveitic macular oedema
1 August 2014
| Efrosini Papagiannuli
|
Retina / Uvea / Vitreous
Epiretinal membrane (ERM) formation in uveitic macular oedema is a fairly common structural complication of the retina. The authors describe a retrospective case series of 104 eyes of 77 patients with uveitic macular oedema from a tertiary centre. The treatment...
Cystoid macular oedema following cataract surgery
1 October 2019
| Ivan Yip
|
Cataract and Refractive
|
NSAIDs, cataract, cataract surgery, corticosteroids, cystoid macular oedema
This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...
Outcomes of treat & extend ranibizumab in diabetic macular oedema
1 October 2021
| Ed Rule
|
Retina / Uvea / Vitreous
|
Diabetic macular edema, Outcome predictor, Ranibizumab, Spectral-domain optical coherence tomography, Treat and extend
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...
Steroid treatment for pseudophakic cystoid macular oedema
1 October 2021
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Cystoid macular edema, intravitreal steroids, triamcinolone
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Cystoid macular oedema following retinal detachment surgery
5 April 2022
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Cystoid macular edema, rhegmatogenous retinal detachment, vitreoretinal surgery
There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...
Management of diabetic macular oedema in vitrectomised eyes
1 August 2016
| Maged Habib
|
Retina / Uvea / Vitreous
Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....